loading...| Preferred Name |
Dapagliflozin |
|
| Synonyms |
D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-, Compd. with (2S)-1,2-propanediol, Hydrate (1:1:1) DAPAGLIFLOZIN Dapagliflozin BMS-512148-05 |
|
| Definitions |
A selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Dapagliflozin selectively and potently inhibits SGLT2 compared to SGLT1, which is the cotransporter of glucose in the gut. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C78126 |
|
| CAS_Registry |
461432-26-8 |
|
| Chemical_Formula |
C21H25ClO6 |
|
| code |
C78126 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 |
|
| Contributing_Source |
CTRP FDA |
|
| DEFINITION |
A selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Dapagliflozin selectively and potently inhibits SGLT2 compared to SGLT1, which is the cotransporter of glucose in the gut. |
|
| Display_Name |
Dapagliflozin |
|
| FDA_UNII_Code |
1ULL0QJ8UC |
|
| FULL_SYN |
D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-, Compd. with (2S)-1,2-propanediol, Hydrate (1:1:1) DAPAGLIFLOZIN Dapagliflozin BMS-512148-05 |
|
| Has_Target | ||
| label |
Dapagliflozin |
|
| Legacy Concept Name |
Dapagliflozin |
|
| NCI_Drug_Dictionary_ID |
802820 |
|
| PDQ_Closed_Trial_Search_ID |
802820 |
|
| PDQ_Open_Trial_Search_ID |
802820 |
|
| Preferred_Name |
Dapagliflozin |
|
| prefixIRI |
Thesaurus:C78126 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C2353951 |
|
| subClassOf |